Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer

Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Dades bibliogràfiques
Autor principal:	Flora, Sanzida Alam
Altres autors:	Azam, Faruque
Format:	Thesis
Idioma:	English
Publicat:	Brac University 2024
Matèries:	NSCLC Tyrosine kinase inhibitor Efficacy endpoints Cancer therapy Lung cancer Lung cancer > Treatment Protein-tyrosine kinase > Inhibitors > Therapeutic use
Accés en línia:	http://hdl.handle.net/10361/23693

Ítems similars

A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
per: Khan, Muidul Hasan
Publicat: (2024)

Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
per: Paul, Pulock
Publicat: (2024)

Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
per: Rahman, Tasnim
Publicat: (2024)

A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
per: Sorno, Rubina Haque
Publicat: (2024)

Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
per: Hoque, Ismoth Ara
Publicat: (2024)

Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
per: Karim, Samia Binte
Publicat: (2024)

Immunotherapy in the Management of Lung Cancer
per: Tasnim, Humayra
Publicat: (2022)

Molecules associated with the development of lung cancer
per: Rahman, Adree, et al.
Publicat: (2023)

Protein biomarkers for Lung Cancer: a bioinformatic approach
per: Jeba, Joynob
Publicat: (2017)

SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
per: Meem, Manila
Publicat: (2023)

A review on targeted therapies for lung cancer
per: Ashraf, Anushey
Publicat: (2023)

Potential of liposomes for the treatment of lung cancer- a review
per: Mim, Shanzida
Publicat: (2023)

A review on recent advances in drugs for lung cancer treatment
per: Noor, Fouzia
Publicat: (2024)

A review on potential of PARP inhibitors in the treatment of prostate cancer
per: Islam, Saidul
Publicat: (2022)

Computational insights into molecular docking strategies for non-small cell lung cancer drug discovery
per: Das, Reshita
Publicat: (2024)

A cross-sectional study on risk factors, symptoms, treatment and management strategies of lung cancer in a tertiary care cancer hospital of Bangladesh
per: Pial, Sazia Afrin
Publicat: (2018)

Recent developments in the Adeno-Associated Viral Gene Therapy for Non-Small Cell Lung Cancer during the past 20 years
per: Razna, Amrin Islam
Publicat: (2019)

Pooled analysis of progression-free survival and overall survival in phase II clinical trials of breast cancer
per: Shobnam, Sohana
Publicat: (2024)

A case study of lung cancer patients in term of various risk factors in context of Bangladesh
per: Shabnam, Musharrat
Publicat: (2018)

Bioinformatics analyses of key regulators of NF-κB pathway in relation with small cell lung carcinoma
per: Zangmo, Thinley
Publicat: (2024)

Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
per: Tania, Umme
Publicat: (2023)

In silico modelling and structural dynamics of PSY1R kinase domain and its interaction with SERK1 kinase
per: Ruhee, Noshin Nawer
Publicat: (2022)

RIPK pathway, as a potential target, for cancer treatment - a review
per: Jahan, Nusrat
Publicat: (2024)

An overview of the clinical management and challenges of treatments for the patients diagnosed with COVID-19 and lung carcinoma
per: Bristy, Israt Zerin
Publicat: (2021)

Lung cancer detection and classification using machine learning
per: Arefin, Mahbubul, et al.
Publicat: (2023)

A review on newly approved PARP inhibitors: Talazoparib and Olaparib
per: Karim, Azrin
Publicat: (2024)

A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease
per: Haque, Mushfiqul
Publicat: (2019)

Score based risk assessment of lung cancer and its evaluation for Bangladeshi people
per: Mukti, Roushney Fatima, et al.
Publicat: (2016)

A review on insulin-producing beta cell: regenerative role of drugs acting on DYRK1A, GLP-1 and DPP-4 receptors
per: Mahmood, Nyrit
Publicat: (2021)

A review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapy
per: Ratu, Tabassum
Publicat: (2024)

Tamoxifen: The ideal post operative hormonal therapy to demote Ductal Carcinoma in Situ
per: Mirza, Maisa Tasnim
Publicat: (2023)

Lung cancer immunosuppression and therapeutic targeting of myeloid- derived suppressor cells
per: Nandy, Aditi
Publicat: (2022)

Statistics and informatics in molecular cancer research

An examination of therapeutic synergy: a comprehensive meta-analysis comparing the efficacy of TAS-102 and FOLFOX as a combination therapy for colon cancer
per: Hasan, Amit
Publicat: (2024)

Identification of FAP inhibitors using in silico simulation study
per: Deeba, Maliha Tasnim
Publicat: (2018)

Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
per: Abir, Shifaty Nur
Publicat: (2024)

Evaluation of genetics of cancer predisposition in patients and efficacy of various chemotherapeutic drugs in Bangladesh
per: Hossain, Safa Binte
Publicat: (2019)

Recent advances in Cancer treatment targeting autophagy and future aspects
per: Emon, Kamrul Hasan
Publicat: (2022)

Cancer risk factors: a critical review
per: Tabassum, Tahsina
Publicat: (2017)

Survey on patients undergoing treatments for cervical, endometrial and ovarian cancer
per: Nawar, Anika
Publicat: (2019)